Seattle biotech agency Impel NeuroPharma information for $75M IPO

Seattle biotech firm Impel NeuroPharma files for $75M IPO

Impel CEO Adrian Adams. (Impel Photograph)

Seattle-based biotech firm Impel NeuroPharma is about to go public. The corporate, which develops medicine for central nervous system issues corresponding to migraines and Parkinson’s, submitted paperwork on Friday for a $75 million IPO.

Based in 2008, Impel is a late-stage pre-revenue pharma firm identified for its Precision Olfactory Supply (POD) platform, which sends medicine into the nasal cavity with the purpose of penetrating the blood-brain barrier and focusing on the organ extra instantly than is feasible with capsules or injected medicine. Its lead candidate, a drug that treats migraines referred to as TRUDHESA, goes by the FDA’s New Drug Software course of.

The corporate has raised $140 million so far from backers together with KKR, Norwest Enterprise Companions, 5AM Ventures, Vivo Capital, and VenBio Companions. Impel was co-founded by John Hoekman, who first developed the POD system whereas in graduate college on the College of Washington. The corporate is led by Adrian Adams, a biotech vet who took over for Jon Congleton final 12 months.

Impel plans to commerce below the ticker IMPL on the Nasdaq. It will be the primary Washington state firm to go public in 2021 by way of a standard IPO.

What do you think?

Written by LessDaily.Com


Leave a Reply

Your email address will not be published. Required fields are marked *


The word coronavirus on pink paper surrounded by scattered vitamins and supplements; COVID-19.

Do vitamin D, zinc, and different dietary supplements assist forestall COVID-19 or hasten therapeutic? – Harvard Well being Weblog

These startups are solving Amazon’s potty problem, helping delivery drivers find relief on the go

These startups are fixing Amazon’s potty downside, serving to supply drivers discover reduction on the go